BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kokudo T, Hasegawa K, Matsuyama Y, Takayama T, Izumi N, Kadoya M, Kudo M, Ku Y, Sakamoto M, Nakashima O, Kaneko S, Kokudo N;  Liver Cancer Study Group of Japan. Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. J Hepatol. 2016;65:938-943. [PMID: 27266618 DOI: 10.1016/j.jhep.2016.05.044] [Cited by in Crossref: 156] [Cited by in F6Publishing: 152] [Article Influence: 26.0] [Reference Citation Analysis]
Number Citing Articles
1 Lau WY. Commentary on the article entitled "hepatocellular carcinoma with macrovascular invasion treated with yttrium-90 radioembolization prior to transplantation". Hepatobiliary Surg Nutr 2017;6:49-51. [PMID: 28261595 DOI: 10.21037/hbsn.2017.01.09] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
2 Mähringer-kunz A, Steinle V, Düber C, Weinmann A, Koch S, Schmidtmann I, Schotten S, Hinrichs JB, Graafen D, Pinto dos Santos D, Galle PR, Kloeckner R. Extent of portal vein tumour thrombosis in patients with hepatocellular carcinoma: The more, the worse? Liver Int 2019;39:324-31. [DOI: 10.1111/liv.13988] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
3 Cortese S, Morales J, Martín L, Kayser S, Colón A, Ramón E, Tellado JM. Resección hepática con trombectomía en el tratamiento del carcinoma hepatocelular con invasión vascular macroscópica. Cirugía Española 2020;98:9-17. [DOI: 10.1016/j.ciresp.2019.06.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Kulik L, El-Serag HB. Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology. 2019;156:477-491.e1. [PMID: 30367835 DOI: 10.1053/j.gastro.2018.08.065.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Xu L, Li L, Wang P, Zhang M, Zhang Y, Hao X, Yan L, Li B, Wen T, Xu M. Novel Prognostic Nomograms for Hepatocellular Carcinoma Patients with Microvascular Invasion: Experience from a Single Center. Gut Liver 2019;13:669-82. [PMID: 30970430 DOI: 10.5009/gnl18489] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
6 Zamora-Valdes D, Taner T, Nagorney DM. Surgical Treatment of Hepatocellular Carcinoma. Cancer Control 2017;24:1073274817729258. [PMID: 28975836 DOI: 10.1177/1073274817729258] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
7 Shehta A, Farouk A, Elghawalby AN, Elshobary M, Aboelenin A, Fouad A, Ali MA. Outcomes of Hepatic Resection for Hepatocellular Carcinoma Associated with Portal Vein Invasion. J Surg Res 2021;266:269-83. [PMID: 34038849 DOI: 10.1016/j.jss.2021.04.011] [Reference Citation Analysis]
8 Sun B, Zhang W, Chen L, Sun T, Ren Y, Zhu L, Qian K, Zheng C. The safety and efficacy of percutaneous ethanol injection in the treatment of tumor thrombus in advanced hepatocellular carcinoma with portal vein tumor thrombus. Abdom Radiol (NY) 2022;47:858-68. [PMID: 34820688 DOI: 10.1007/s00261-021-03349-5] [Reference Citation Analysis]
9 Cai H, Zhang Y, Zhang H, Cui C, Li C, Lu S. Prognostic role of tumor mutation burden in hepatocellular carcinoma after radical hepatectomy. J Surg Oncol 2020;121:1007-14. [PMID: 31995247 DOI: 10.1002/jso.25859] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
10 Zhang ZQ, Xiong L, Zhou JJ, Miao XY, Li QL, Wen Y, Zou H. Ability of the ALBI grade to predict posthepatectomy liver failure and long-term survival after liver resection for different BCLC stages of HCC. World J Surg Oncol. 2018;16:208. [PMID: 30326907 DOI: 10.1186/s12957-018-1500-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
11 Barry A, Apisarnthanarax S, O'Kane GM, Sapisochin G, Beecroft R, Salem R, Yoon SM, Lim YS, Bridgewater J, Davidson B, Scorsetti M, Solbiati L, Diehl A, Schuffenegger PM, Sham JG, Cavallucci D, Galvin Z, Dawson LA, Hawkins MA. Management of primary hepatic malignancies during the COVID-19 pandemic: recommendations for risk mitigation from a multidisciplinary perspective. Lancet Gastroenterol Hepatol. 2020;5:765-775. [PMID: 32511951 DOI: 10.1016/s2468-1253(20)30182-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 6.5] [Reference Citation Analysis]
12 Li M, Zhao Y, Liu X, Zhang S, Jiang Y, Yang Z. Early risk warning system for distant metastasis of hepatitis B virus-associated hepatocellular carcinoma with portal vein tumor thrombus. Oncol Lett 2020;19:3249-57. [PMID: 32256820 DOI: 10.3892/ol.2020.11423] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
13 Fukumoto T, Kido M, Takebe A, Tanaka M, Kinoshita H, Kuramitsu K, Komatsu S, Tsugawa D, Goto T, Asari S, Toyama H, Ajiki T, Ku Y. New macroscopic classification and back-flow thrombectomy for advanced hepatocellular carcinoma with portal vein tumor thrombus invading the contralateral second portal branch. Surg Today. 2017;47:1094-1103. [PMID: 28324163 DOI: 10.1007/s00595-017-1507-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
14 Zhang X, Li J, Shen F, Lau WY. Significance of presence of microvascular invasion in specimens obtained after surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol. 2018;33:347-354. [PMID: 28589639 DOI: 10.1111/jgh.13843] [Cited by in Crossref: 54] [Cited by in F6Publishing: 61] [Article Influence: 13.5] [Reference Citation Analysis]
15 Sato Y, Nishiofuku H, Yasumoto T, Nakatsuka A, Matsuo K, Kodama Y, Okubo H, Abo D, Takaki H, Inaba Y, Yamakado K. Multicenter Phase II Clinical Trial of Sorafenib Combined with Transarterial Chemoembolization for Advanced Stage Hepatocellular Carcinomas (Barcelona Clinic Liver Cancer Stage C): STAB Study. J Vasc Interv Radiol 2018;29:1061-7. [PMID: 29934260 DOI: 10.1016/j.jvir.2018.03.020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
16 Jiang JF, Lao YC, Yuan BH, Yin J, Liu X, Chen L, Zhong JH. Treatment of hepatocellular carcinoma with portal vein tumor thrombus: advances and challenges. Oncotarget 2017;8:33911-21. [PMID: 28430610 DOI: 10.18632/oncotarget.15411] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 7.8] [Reference Citation Analysis]
17 Yamamoto M, Kobayashi T, Honmyo N, Oshita A, Abe T, Kohashi T, Onoe T, Fukuda S, Omori I, Imaoka Y, Ohdan H. Liver resection is associated with good outcomes for hepatocellular carcinoma patients beyond the Barcelona Clinic Liver Cancer criteria: A multicenter study with the Hiroshima Surgical study group of Clinical Oncology. Surgery 2021:S0039-6060(21)00891-6. [PMID: 34756748 DOI: 10.1016/j.surg.2021.09.009] [Reference Citation Analysis]
18 Bae B, Song SK, Choi E, Chung CW, Park Y. Secondarily estimated cure fraction and five-year recurrence-free conditional survival probabilities among patients undergoing surgical resection for hepatocellular carcinoma presenting with minor gross vascular invasion. World J Surg Oncol 2021;19:222. [PMID: 34311741 DOI: 10.1186/s12957-021-02331-1] [Reference Citation Analysis]
19 Sun X, Zhang Q, Mei J, Yang Z, Chen M, Liang T. Real-world efficiency of lenvatinib plus PD-1 blockades in advanced hepatocellular carcinoma: an exploration for expanded indications. BMC Cancer 2022;22. [DOI: 10.1186/s12885-022-09405-7] [Reference Citation Analysis]
20 Xu W, Rao Q, An Y, Li M, Zhang Z. Identification of biomarkers for Barcelona Clinic Liver Cancer staging and overall survival of patients with hepatocellular carcinoma. PLoS One 2018;13:e0202763. [PMID: 30138346 DOI: 10.1371/journal.pone.0202763] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
21 Lv JY, Zhang NN, Du YW, Wu Y, Song TQ, Zhang YM, Qu Y, Liu YX, Gu J, Wang ZY, Qiu YB, Yang B, Tian DZ, Guo QJ, Zhang L, Sun JS, Xie Y, Wang ZL, Sun X, Jiang WT, Lu W. Comparison of Liver Transplantation and Liver Resection for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus Type I and Type II. Yonsei Med J 2021;62:29-40. [PMID: 33381932 DOI: 10.3349/ymj.2021.62.1.29] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
22 Chen ZH, Wang K, Zhang XP, Feng JK, Chai ZT, Guo WX, Shi J, Wu MC, Lau WY, Cheng SQ. A new classification for hepatocellular carcinoma with hepatic vein tumor thrombus. Hepatobiliary Surg Nutr. 2020;9:717-728. [PMID: 33299827 DOI: 10.21037/hbsn.2019.10.07] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
23 Walcott-Sapp S, Billingsley KG. Preoperative optimization for major hepatic resection. Langenbecks Arch Surg 2018;403:23-35. [PMID: 29150719 DOI: 10.1007/s00423-017-1638-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
24 Ogasawara S, Koroki K, Kanzaki H, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Nakagawa R, Nakamoto S, Muroyama R, Chiba T, Kato N. Changes in therapeutic options for hepatocellular carcinoma in Asia. Liver Int 2021. [PMID: 34780081 DOI: 10.1111/liv.15101] [Reference Citation Analysis]
25 Liu S, Zhou Z, Jia Y, Xue J, Liu Z, Cheng K, Cheng S, Liu S. Identification of portal vein tumor thrombus with an independent clonal origin in hepatocellular carcinoma via multi-omics data analysis. Cancer Biol Med 2019;16:147-70. [PMID: 31119055 DOI: 10.20892/j.issn.2095-3941.2018.0184] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
26 Yin J, Bo WT, Sun J, Xiang X, Lang JY, Zhong JH, Li LQ. New Evidence and Perspectives on the Management of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. J Clin Transl Hepatol. 2017;5:169-176. [PMID: 28660155 DOI: 10.14218/jcth.2016.00071] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
27 Feng JK, Sun JX, Liu ZH, Cheng SQ. Hepatocellular Carcinoma with Portal Vein Tumor Thrombus versus Hepatocellular Carcinoma with Biliary Tumor Thrombus: Better or Worse Prognoses? [Letter]. Cancer Manag Res 2021;13:987-8. [PMID: 33568944 DOI: 10.2147/CMAR.S299132] [Reference Citation Analysis]
28 Qadan M, Kothary N, Sangro B, Palta M. The Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis. Am Soc Clin Oncol Educ Book 2020;40:1-8. [PMID: 32213090 DOI: 10.1200/EDBK_280811] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
29 Waziry R, Gomaa A, Waked I, Dore GJ. Determinants of survival following hepatocellular carcinoma in Egyptian patients with untreated chronic HCV infection in the pre-DAA era. Arab J Gastroenterol 2018;19:26-32. [PMID: 29506913 DOI: 10.1016/j.ajg.2018.02.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
30 Kudo M. Surveillance, Diagnosis, and Treatment Outcomes of Hepatocellular Carcinoma in Japan: 2021 Update. Liver Cancer 2021;10:167-80. [PMID: 34239807 DOI: 10.1159/000516491] [Reference Citation Analysis]
31 Zhu J, Yin T, Xu Y, Lu XJ. Therapeutics for advanced hepatocellular carcinoma: Recent advances, current dilemma, and future directions. J Cell Physiol. 2019;234:12122-12132. [PMID: 30644100 DOI: 10.1002/jcp.28048] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 6.7] [Reference Citation Analysis]
32 Bai S, Wu Y, Yan Y, Li R, Kang H, Zhang J, Ma W, Gao Y, Hui B, Ma H, Zhang X, Ren J. Evaluation of the Efficacy and Toxicity of Radiotherapy for Type III-IV Portal Vein Tumor Thrombi. Technol Cancer Res Treat 2021;20:1533033821995286. [PMID: 33590809 DOI: 10.1177/1533033821995286] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
33 Huang Q, Chen Y, Lin K, Sun C, Zheng S, Chen J, Wang Y, Zhou Y, Zhou W, Liu J, Zeng Y. Redefining Hepatocellular Carcinoma Staging Systems Based on the Bile Duct Invasion Status: A Multicenter Study. Front Oncol 2021;11:673285. [PMID: 34722235 DOI: 10.3389/fonc.2021.673285] [Reference Citation Analysis]
34 Pelizzaro F, Haxhi S, Penzo B, Vitale A, Giannini EG, Sansone V, Rapaccini GL, Di Marco M, Caturelli E, Magalotti D, Sacco R, Celsa C, Campani C, Mega A, Guarino M, Gasbarrini A, Svegliati-baroni G, Foschi FG, Olivani A, Masotto A, Nardone G, Raimondo G, Azzaroli F, Vidili G, Brunetto MR, Trevisani F, Farinati F. Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment. Front Oncol 2022;12:822507. [DOI: 10.3389/fonc.2022.822507] [Reference Citation Analysis]
35 Chen L, Sun T, Chen S, Ren Y, Yang F, Zheng C. The efficacy of surgery in advanced hepatocellular carcinoma: a cohort study. World J Surg Oncol 2020;18:119. [PMID: 32487104 DOI: 10.1186/s12957-020-01887-8] [Reference Citation Analysis]
36 Wu JY, Sun JX, Wu JY, Huang XX, Bai YN, Wei YG, Zhang ZB, Zhou JY, Cheng SQ, Yan ML. Impact of Bile Duct Tumor Thrombus on the Long-Term Surgical Outcomes of Hepatocellular Carcinoma Patients: A Propensity Score Matching Analysis. Ann Surg Oncol 2021. [PMID: 34591226 DOI: 10.1245/s10434-021-10799-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Xu W, Rao Q, An Y, Li M, Xu G, Sang X, Lu X, Zhang Z, Mao Y. Proposal for subclassification to select patients for hepatectomy with intermediate hepatocellular carcinoma and Child-Pugh A liver function: A double-center study from China. Medicine (Baltimore). 2018;97:e11800. [PMID: 30095644 DOI: 10.1097/md.0000000000011800] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
38 Kim N, You MW. Hepatocellular carcinoma and macrovascular tumor thrombosis: treatment outcomes and prognostic factors for survival. Jpn J Radiol 2019;37:781-92. [PMID: 31522384 DOI: 10.1007/s11604-019-00868-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
39 Blaise L, Pereira H, Vilgrain V, Sutter O, Gigante E, Walter A, Ganne-Carrié N, Nahon P, Bouattour M, Dioguardi Burgio M, Grando V, Nkontchou G, Seror O, Nault JC. Percutaneous ablation for locally advanced hepatocellular carcinoma with tumor portal invasion. Clin Res Hepatol Gastroenterol 2021;45:101731. [PMID: 34139320 DOI: 10.1016/j.clinre.2021.101731] [Reference Citation Analysis]
40 Su TH, Hsu SJ, Kao JH. Paradigm shift in the treatment options of hepatocellular carcinoma. Liver Int 2021. [PMID: 34515412 DOI: 10.1111/liv.15052] [Reference Citation Analysis]
41 Kamiyama T, Kakisaka T, Orimo T, Wakayama K. Hepatectomy for hepatocellular carcinoma with portal vein tumor thrombus. World J Hepatol 2017; 9(36): 1296-1304 [PMID: 29359012 DOI: 10.4254/wjh.v9.i36.1296] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
42 Cheung TT, Han HS, She WH, Chen KH, Chow PKH, Yoong BK, Lee KF, Kubo S, Tang CN, Wakabayashi G. The Asia Pacific Consensus Statement on Laparoscopic Liver Resection for Hepatocellular Carcinoma: A Report from the 7th Asia-Pacific Primary Liver Cancer Expert Meeting Held in Hong Kong. Liver Cancer. 2018;7:28-39. [PMID: 29662831 DOI: 10.1159/000481834] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 5.2] [Reference Citation Analysis]
43 Mähringer-Kunz A, Steinle V, Kloeckner R, Schotten S, Hahn F, Schmidtmann I, Hinrichs JB, Düber C, Galle PR, Lang H, Weinmann A. The impact of portal vein tumor thrombosis on survival in patients with hepatocellular carcinoma treated with different therapies: A cohort study. PLoS One 2021;16:e0249426. [PMID: 33961627 DOI: 10.1371/journal.pone.0249426] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Kokudo T, Kokudo N. What liver surgeons have achieved in the recent decade for patients with hepatocellular carcinoma? Glob Health Med 2020;2:265-8. [PMID: 33330819 DOI: 10.35772/ghm.2020.01086] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
45 Choe JW, Lee HY, Rim CH. Will the collaboration of surgery and external radiotherapy open new avenues for hepatocellular carcinoma with portal vein thrombosis? World J Gastroenterol 2022; 28(7): 704-714 [DOI: 10.3748/wjg.v28.i7.704] [Reference Citation Analysis]
46 Tsurugai Y, Takeda A, Sanuki N, Eriguchi T, Ueno M. Three Cases of Hepatocellular Carcinoma With Massive Macrovascular Invasion Successfully Treated With Radiotherapy. Cureus 2021;13:e18624. [PMID: 34765376 DOI: 10.7759/cureus.18624] [Reference Citation Analysis]
47 Lau WY, Wang K, Zhang XP, Li LQ, Wen TF, Chen MS, Jia WD, Xu L, Shi J, Guo WX, Sun JX, Chen ZH, Guo L, Wei XB, Lu CD, Xue J, Zhou LP, Zheng YX, Wang M, Wu MC, Cheng SQ. A new staging system for hepatocellular carcinoma associated with portal vein tumor thrombus. Hepatobiliary Surg Nutr 2021;10:782-95. [PMID: 35004945 DOI: 10.21037/hbsn-19-810] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
48 Kudo M. Management of Hepatocellular Carcinoma in Japan as a World-Leading Model. Liver Cancer 2018;7:134-47. [PMID: 29888204 DOI: 10.1159/000484619] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
49 Zhang XP, Chai ZT, Gao YZ, Chen ZH, Wang K, Shi J, Guo WX, Zhou TF, Ding J, Cong WM, Xie D, Lau WY, Cheng SQ. Postoperative adjuvant sorafenib improves survival outcomes in hepatocellular carcinoma patients with microvascular invasion after R0 liver resection: a propensity score matching analysis. HPB (Oxford) 2019;21:1687-96. [PMID: 31153833 DOI: 10.1016/j.hpb.2019.04.014] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
50 Hu J, Bao Q, Cao G, Zhu X, Yang R, Ji X, Xu L, Zheng K, Li W, Xing B, Wang X. Hepatic Arterial Infusion Chemotherapy Using Oxaliplatin Plus 5-Fluorouracil Versus Transarterial Chemoembolization/Embolization for the Treatment of Advanced Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis. Cardiovasc Intervent Radiol 2020;43:996-1005. [PMID: 31974744 DOI: 10.1007/s00270-019-02406-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
51 Ma KW, Chan ACY, Chok KSH, She WH, Cheung TT, Dai WC, Fung JYY, Lo CM. Liver transplantation: would it be the best and last chance of cure for hepatocellular carcinoma with major venous invasion? Hepatobiliary Surg Nutr 2021;10:308-14. [PMID: 34159158 DOI: 10.21037/hbsn.2020.03.09] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Kulik L, El-Serag HB. Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology. 2019;156:477-491.e1. [PMID: 30367835 DOI: 10.1053/j.gastro.2018.08.065] [Cited by in Crossref: 365] [Cited by in F6Publishing: 367] [Article Influence: 91.3] [Reference Citation Analysis]
53 Wang YY, Zhong JH, Mao YL, Li LQ, Xing BC. Editorial: redrawing the boundaries for surgical intervention in hepatocellular carcinoma-authors' reply. Aliment Pharmacol Ther 2019;49:616-7. [PMID: 30746777 DOI: 10.1111/apt.15142] [Reference Citation Analysis]
54 Zhang XP, Zhou TF, Feng JK, Sun ZY, Zhen ZJ, Zhou D, Zhang F, Hu YR, Zhong CQ, Chen ZH, Chai ZT, Wang K, Shi J, Guo WX, Wu MC, Lau WY, Cheng SQ. Association of Preoperative Coagulability With Incidence and Extent of Portal Vein Tumor Thrombus and Survival Outcomes in Hepatocellular Carcinoma After Hepatectomy: A Large-Scale, Multicenter Study. Front Oncol 2021;11:697073. [PMID: 34395264 DOI: 10.3389/fonc.2021.697073] [Reference Citation Analysis]
55 Sun HC, Zhu XD, Zhou J, Gao Q, Shi YH, Ding ZB, Huang C, Qiu SJ, Ren N, Shi GM, Sun J, Ye QH, Huang XW, Yang XR, Fan J. Adjuvant apatinib treatment after resection of hepatocellular carcinoma with portal vein tumor thrombosis: a phase II trial. Ann Transl Med 2020;8:1301. [PMID: 33209881 DOI: 10.21037/atm-20-6181] [Reference Citation Analysis]
56 Ito K, Takemura N, Inagaki F, Mihara F, Kokudo N. Difference in treatment algorithms for hepatocellular carcinoma between world's principal guidelines. Glob Health Med. 2020;2:282-291. [PMID: 33330822 DOI: 10.35772/ghm.2020.01066] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
57 Meng XY, Zhang XP, Sun Z, Wang HQ, Yu WF. Distant survival for patients undergoing surgery using volatile versus IV anesthesia for hepatocellular carcinoma with portal vein tumor thrombus: a retrospective study. BMC Anesthesiol 2020;20:233. [PMID: 32928121 DOI: 10.1186/s12871-020-01111-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
58 Ratti F, Cipriani F, Fiorentini G, Catena M, Paganelli M, Aldrighetti L. Reappraisal of the advantages of laparoscopic liver resection for intermediate hepatocellular carcinoma within a stage migration perspective: Propensity score analysis of the differential benefit. J Hepatobiliary Pancreat Sci 2020;27:510-21. [PMID: 32189450 DOI: 10.1002/jhbp.736] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
59 Lin JX, Huang YQ, Xie JW, Wang JB, Lu J, Chen QY, Cao LL, Lin M, Tu RH, Huang ZN, Lin JL, Li P, Huang CM, Zheng CH. Age-adjusted Charlson Comorbidity Index (ACCI) is a significant factor for predicting survival after radical gastrectomy in patients with gastric cancer. BMC Surg 2019;19:53. [PMID: 31133008 DOI: 10.1186/s12893-019-0513-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
60 Zhang W, Tan Y, Shen S, Jiang L, Yan L, Yang J, Li B, Wen T, Zeng Y, Wang WT, Xu M. Prognostic nomogram for hepatocellular carcinoma in adolescent and young adult patients after hepatectomy. Oncotarget 2017;8:106393-404. [PMID: 29290957 DOI: 10.18632/oncotarget.18192] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
61 Feng JK, Chen ZH, Wu YX, Wang K, Sun JX, Chai ZT, Guo WX, Shi J, Cheng SQ. Comparison of different surgical interventions for hepatocellular carcinoma with bile duct tumor thrombus: a systematic review and meta-analysis. Ann Transl Med 2020;8:1567. [PMID: 33437766 DOI: 10.21037/atm-20-3935] [Reference Citation Analysis]
62 Zhang XP, Wang K, Li N, Zhong CQ, Wei XB, Cheng YQ, Gao YZ, Wang H, Cheng SQ. Survival benefit of hepatic resection versus transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis. BMC Cancer 2017;17:902. [PMID: 29282010 DOI: 10.1186/s12885-017-3895-z] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
63 Yen YH, Li WF, Kee KM, Wang CC, Cheng YF, Wang JH, Lu SN, Hung CH. The characteristics of patients with macrovascular invasion in hepatocellular carcinoma: when East meets West. Langenbecks Arch Surg 2021. [PMID: 34825277 DOI: 10.1007/s00423-021-02370-y] [Reference Citation Analysis]
64 Zhao J, Xie Y. Progress in research of hepatocellular carcinoma with tumor thrombus. Shijie Huaren Xiaohua Zazhi 2019; 27(20): 1239-1247 [DOI: 10.11569/wcjd.v27.i20.1239] [Reference Citation Analysis]
65 Liu T, Shao Y, Lu L, Shen Y, Hsu C, Lin Z, Hsu C, Cheng A. Considerations of heterogeneity in clinical trials for hepatocellular carcinoma. Expert Review of Gastroenterology & Hepatology 2019;13:615-21. [DOI: 10.1080/17474124.2019.1621165] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
66 Aoki T, Kubota K, Kubo S, Eguchi S, Izumi N, Kokudo N, Sakamoto M, Shiina S, Takayama T, Nakashima O, Matsuyama Y, Murakami T, Kudo M. Analysis of Patient Outcome after Non-curative Resection for Hepatocellular Carcinoma Using Nationwide Survey Data in Japan. World J Surg 2021;45:607-14. [PMID: 33104834 DOI: 10.1007/s00268-020-05830-6] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
67 Zhang XP, Liu YC, Chen ZH, Sun JX, Wang K, Chai ZT, Shi J, Guo WX, Wu MC, Lau WY, Cheng SQ. Postoperative Adjuvant Transarterial Chemoembolization Improves Outcomes of Hepatocellular Carcinoma Associated with Hepatic Vein Invasion: A Propensity Score Matching Analysis. Ann Surg Oncol 2019;26:1465-73. [PMID: 30767178 DOI: 10.1245/s10434-019-07223-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
68 Soin AS, Bhangui P, Kataria T, Baijal SS, Piplani T, Gautam D, Choudhary NS, Thiagarajan S, Rastogi A, Saraf N, Saigal S. Experience With LDLT in Patients With Hepatocellular Carcinoma and Portal Vein Tumor Thrombosis Postdownstaging. Transplantation 2020;104:2334-45. [PMID: 32032291 DOI: 10.1097/TP.0000000000003162] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 11.0] [Reference Citation Analysis]
69 Chai ZT, Zhang XP, Ao JY, Zhu XD, Wu MC, Lau WY, Sun HC, Cheng SQ. AXL Overexpression in Tumor-Derived Endothelial Cells Promotes Vessel Metastasis in Patients With Hepatocellular Carcinoma. Front Oncol 2021;11:650963. [PMID: 34123800 DOI: 10.3389/fonc.2021.650963] [Reference Citation Analysis]
70 Hu XG, Shen XY, Nan JN, Kim IG, Yoon JK, Hong SY, Kim MN, Kim BW, Wang HJ. 18F-fluorodeoxyglucose PET/CT as an independent predictor for patients with hepatocellular carcinoma combined with major portal vein tumor thrombus. Ann Surg Treat Res 2020;99:8-17. [PMID: 32676477 DOI: 10.4174/astr.2020.99.1.8] [Reference Citation Analysis]
71 Takayama T, Yamazaki S, Matsuyama Y, Midorikawa Y, Shiina S, Izumi N, Hasegawa K, Kokudo N, Sakamoto M, Kubo S, Kudo M, Murakami T, Nakashima O; Liver Cancer Study Group of Japan. Prognostic grade for resecting hepatocellular carcinoma: multicentre retrospective study. Br J Surg 2021;108:412-8. [PMID: 33793713 DOI: 10.1093/bjs/znaa109] [Reference Citation Analysis]
72 Kudo M. Changing the Treatment Paradigm for Hepatocellular Carcinoma Using Atezolizumab plus Bevacizumab Combination Therapy. Cancers (Basel) 2021;13:5475. [PMID: 34771637 DOI: 10.3390/cancers13215475] [Reference Citation Analysis]
73 Levi Sandri GB, Rayar M. How to identify better candidate to radioembolization in case of hepatocellular carcinoma and portal vein tumoral thrombosis. Hepatobiliary Surg Nutr 2019;8:63-4. [PMID: 30881968 DOI: 10.21037/hbsn.2018.11.03] [Reference Citation Analysis]
74 Kudo M, Izumi N, Kokudo N, Sakamoto M, Shiina S, Takayama T, Tateishi R, Nakashima O, Murakami T, Matsuyama Y, Takahashi A, Miyata H, Kubo S. Report of the 21st Nationwide Follow-up Survey of Primary Liver Cancer in Japan (2010-2011). Hepatol Res 2021;51:355-405. [PMID: 33382910 DOI: 10.1111/hepr.13612] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
75 Zhang ZY, Dong KS, Zhang EL, Zhang LW, Chen XP, Dong HH. Resection might be a meaningful choice for hepatocellular carcinoma with portal vein thrombosis: A systematic review and meta-analysis. Medicine (Baltimore) 2019;98:e18362. [PMID: 31852141 DOI: 10.1097/MD.0000000000018362] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
76 Ryon EL, Kronenfeld JP, Lee RM, Yopp A, Wang A, Lee AY, Luu S, Hsu C, Silberfein E, Russell MC, Goel N, Merchant NB, Datta J. Surgical management of hepatocellular carcinoma patients with portal vein thrombosis: The United States Safety Net and Academic Center Collaborative Analysis. J Surg Oncol 2021;123:407-15. [PMID: 33125746 DOI: 10.1002/jso.26282] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
77 Hamaoka M, Kobayashi T, Kuroda S, Iwako H, Okimoto S, Kimura T, Aikata H, Nagata Y, Chayama K, Ohdan H. Hepatectomy after down-staging of hepatocellular carcinoma with portal vein tumor thrombus using chemoradiotherapy: A retrospective cohort study. International Journal of Surgery 2017;44:223-8. [DOI: 10.1016/j.ijsu.2017.06.082] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
78 Tsujita Y, Sofue K, Komatsu S, Yamaguchi T, Ueshima E, Ueno Y, Kanda T, Okada T, Nogami M, Yamaguchi M, Tsurusaki M, Hori M, Fukumoto T, Murakami T. Prediction of post-hepatectomy liver failure using gadoxetic acid-enhanced magnetic resonance imaging for hepatocellular carcinoma with portal vein invasion. Eur J Radiol 2020;130:109189. [PMID: 32784077 DOI: 10.1016/j.ejrad.2020.109189] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
79 Liang L, Chen TH, Li C, Xing H, Han J, Wang MD, Zhang H, Lau WY, Wu MC, Shen F, Yang T. A systematic review comparing outcomes of surgical resection and non-surgical treatments for patients with hepatocellular carcinoma and portal vein tumor thrombus. HPB (Oxford). 2018;20:1119-1129. [PMID: 30056066 DOI: 10.1016/j.hpb.2018.06.1804] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
80 Walcott-Sapp S, Naugler S, Lim JY, Wagner J, Orloff SL, Farsad K, Kolbeck KJ, Kaufman J, Maynard E, Enestvedt CK, Mayo SC, Billingsley KG. Tailored treatment of patients with hepatocellular carcinoma with portal vein invasion: experience from a multidisciplinary hepatobiliary tumor program within a NCI comprehensive cancer center. J Gastrointest Oncol 2018;9:1074-83. [PMID: 30603126 DOI: 10.21037/jgo.2018.08.11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
81 Cheng S, Chen M, Cai J; National Research Cooperative Group for Diagnosis and Treatment of Hepatocellular Carcinoma with Tumor Thrombus. Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus: 2016 edition. Oncotarget. 2017;8:8867-8876. [PMID: 27780939 DOI: 10.18632/oncotarget.12817] [Cited by in Crossref: 27] [Cited by in F6Publishing: 39] [Article Influence: 6.8] [Reference Citation Analysis]
82 Dong X, Sun Z, Wu T, Guo W, Yan S, Zheng S. 915-MHz microwave-assisted laparoscopic hepatectomy: a new technique for liver resection. Surg Endosc 2019;33:395-400. [PMID: 30374791 DOI: 10.1007/s00464-017-5945-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
83 Maki H, Hasegawa K. Advances in the surgical treatment of liver cancer. Biosci Trends 2022. [PMID: 35732434 DOI: 10.5582/bst.2022.01245] [Reference Citation Analysis]
84 Vibert E, Schwartz M, Olthoff KM. Advances in resection and transplantation for hepatocellular carcinoma. J Hepatol. 2020;72:262-276. [PMID: 31954491 DOI: 10.1016/j.jhep.2019.11.017] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 26.0] [Reference Citation Analysis]
85 Allaire M, Goumard C, Lim C, Le Cleach A, Wagner M, Scatton O. New frontiers in liver resection for hepatocellular carcinoma. JHEP Rep. 2020;2:100134. [PMID: 32695968 DOI: 10.1016/j.jhepr.2020.100134] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
86 Zhang Y, Wu JL, Li LQ. Efficacy comparison of optimal treatments for hepatocellular carcinoma patients with portal vein tumor thrombus. Ann Hepatol 2021;27:100552. [PMID: 34614432 DOI: 10.1016/j.aohep.2021.100552] [Reference Citation Analysis]
87 Kuo F, Cheng T, Cheng Y, Wu C, Wang C. Effectiveness of multimodality treatment for hepatocellular carcinoma patients with portal vein thrombosis: A real world experience. Adv in Digestive Med. [DOI: 10.1002/aid2.13275] [Reference Citation Analysis]
88 Sun L, Kong Y, Cao M, Zhou H, Li H, Cui Y, Fang F, Zhang W, Li J, Zhu X, Li Q, Song T, Zhang T. Decreased expression of acetyl-CoA synthase 2 promotes metastasis and predicts poor prognosis in hepatocellular carcinoma. Cancer Sci 2017;108:1338-46. [PMID: 28387999 DOI: 10.1111/cas.13252] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
89 Kudo M, Izumi N, Kubo S, Kokudo N, Sakamoto M, Shiina S, Tateishi R, Nakashima O, Murakami T, Matsuyama Y, Takahashi A, Miyata H, Takayama T. Report of the 20th Nationwide follow-up survey of primary liver cancer in Japan. Hepatol Res 2020;50:15-46. [PMID: 31655492 DOI: 10.1111/hepr.13438] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 25.5] [Reference Citation Analysis]
90 Yang X, Zhu Y, Zhao X, Li JH, Xu D, Jia HL, Zhang JB. The Prognostic Comparison Between Hepatocellular Carcinoma with Portal Vein Tumor Thrombus and Bile Duct Cancer Thrombus After Liver Resection. Cancer Manag Res 2020;12:12077-86. [PMID: 33262656 DOI: 10.2147/CMAR.S278777] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
91 Chai ZT, Zhang XP, Shao M, Ao JY, Chen ZH, Zhang F, Hu YR, Zhong CQ, Lin JH, Fang KP, Wu MC, Lau WY, Cheng SQ. Impact of splenomegaly and splenectomy on prognosis in hepatocellular carcinoma with portal vein tumor thrombus treated with hepatectomy. Ann Transl Med 2021;9:247. [PMID: 33708874 DOI: 10.21037/atm-20-2229] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
92 Takahashi K, Kim J, Takahashi A, Hashimoto S, Doi M, Furuya K, Hashimoto R, Owada Y, Ogawa K, Ohara Y, Akashi Y, Hisakura K, Enomoto T, Shimomura O, Noguchi M, Oda T. Conversion hepatectomy for hepatocellular carcinoma with main portal vein tumour thrombus after lenvatinib treatment: A case report. World J Hepatol 2021; 13(3): 384-392 [PMID: 33815680 DOI: 10.4254/wjh.v13.i3.384] [Reference Citation Analysis]
93 Zhang Y, Lei X, Xu L, Lv X, Xu M, Tang H. Preoperative and postoperative nomograms for predicting early recurrence of hepatocellular carcinoma without macrovascular invasion after curative resection. BMC Surg 2022;22:233. [PMID: 35715787 DOI: 10.1186/s12893-022-01682-0] [Reference Citation Analysis]
94 Kawagishi N. HCC with portal vein tumor thrombosis: how to manage? Hepatol Int 2020;14:609-11. [PMID: 32949378 DOI: 10.1007/s12072-020-10090-6] [Reference Citation Analysis]
95 Lee DW, Yim HJ, Seo YS, Na SK, Kim SY, Suh SJ, Hyun JJ, Jung SW, Jung YK, Koo JS, Kim JH, Yeon JE, Lee SW, Byun KS, Um SH. Prognostic assessment using a new substaging system for Barcelona clinic liver cancer stage C hepatocellular carcinoma: A nationwide study. Liver Int. 2019;39:1109-1119. [PMID: 30972935 DOI: 10.1111/liv.14117] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
96 Lee W, Han HS, Ahn S, Yoon YS, Cho JY, Choi Y. Correlation between Resection Margin and Disease Recurrence with a Restricted Cubic Spline Model in Patients with Resected Hepatocellular Carcinoma. Dig Surg 2018;35:520-31. [PMID: 29342456 DOI: 10.1159/000485805] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
97 Costentin CE, Ferrone CR, Arellano RS, Ganguli S, Hong TS, Zhu AX. Hepatocellular Carcinoma with Macrovascular Invasion: Defining the Optimal Treatment Strategy. Liver Cancer 2017;6:360-74. [PMID: 29234639 DOI: 10.1159/000481315] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
98 Li M, Lin S, Wilson L, Huang P, Wang H, Lai S, Dong L, Xu X, Weng X. Cost-Effectiveness Analysis of Hepatic Arterial Infusion of FOLFOX Combined Sorafenib for Advanced Hepatocellular Carcinoma With Portal Vein Invasion. Front Oncol 2021;11:562135. [PMID: 33767976 DOI: 10.3389/fonc.2021.562135] [Reference Citation Analysis]
99 He MK, Zou RH, Li QJ, Zhou ZG, Shen JX, Zhang YF, Yu ZS, Xu L, Shi M. Phase II Study of Sorafenib Combined with Concurrent Hepatic Arterial Infusion of Oxaliplatin, 5-Fluorouracil and Leucovorin for Unresectable Hepatocellular Carcinoma with Major Portal Vein Thrombosis. Cardiovasc Intervent Radiol. 2018;41:734-743. [PMID: 29327075 DOI: 10.1007/s00270-017-1874-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
100 Takano M, Kokudo T, Miyazaki Y, Kageyama Y, Takahashi A, Amikura K, Sakamoto H. Complete response with sorafenib and transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma. World J Gastroenterol 2016; 22(42): 9445-9450 [PMID: 27895433 DOI: 10.3748/wjg.v22.i42.9445] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
101 Yan L, Ren Y, Qian K, Kan X, Zhang H, Chen L, Liang B, Zheng C. Superselective Transarterial Chemoembolization for Unresectable or "Ablation Unsuitable" Hepatocellular Carcinoma in the Caudate Lobe: A Real World, Single-Center Retrospective Study. Front Oncol 2021;11:678847. [PMID: 34778023 DOI: 10.3389/fonc.2021.678847] [Reference Citation Analysis]
102 Pan YX, Chen JC, Fang AP, Wang XH, Chen JB, Wang JC, He W, Fu YZ, Xu L, Chen MS, Zhang YJ, Li QJ, Zhou ZG. A nomogram predicting the recurrence of hepatocellular carcinoma in patients after laparoscopic hepatectomy. Cancer Commun (Lond) 2019;39:55. [PMID: 31601270 DOI: 10.1186/s40880-019-0404-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
103 Lin CW, Chen YS, Lo GH, Wu TC, Yeh JH, Yeh ML, Dai CY, Huang JF, Chuang WL, Roberts L, Jun DW, Toyoda H, Yasuda S, Nguyen MH, Yu ML. Resubclassification and clinical management for Barcelona Clinic Liver Cancer Stage C hepatocellular carcinoma. Hepatol Int 2021;15:946-56. [PMID: 34008091 DOI: 10.1007/s12072-021-10169-8] [Reference Citation Analysis]
104 Allaire M, Nault J. Advances in management of hepatocellular carcinoma. Current Opinion in Oncology 2017;29:288-95. [DOI: 10.1097/cco.0000000000000378] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
105 Shui Y, Yu W, Ren X, Guo Y, Xu J, Ma T, Zhang B, Wu J, Li Q, Hu Q, Shen L, Bai X, Liang T, Wei Q. Stereotactic body radiotherapy based treatment for hepatocellular carcinoma with extensive portal vein tumor thrombosis. Radiat Oncol 2018;13:188. [PMID: 30253783 DOI: 10.1186/s13014-018-1136-5] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 6.8] [Reference Citation Analysis]
106 Lu J, Zhang X, Zhong B, Lau WY, Madoff DC, Davidson JC, Qi X, Cheng S, Teng G. Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west. The Lancet Gastroenterology & Hepatology 2019;4:721-30. [DOI: 10.1016/s2468-1253(19)30178-5] [Cited by in Crossref: 37] [Cited by in F6Publishing: 28] [Article Influence: 12.3] [Reference Citation Analysis]
107 Famularo S, Donadon M, Cipriani F, Ardito F, Carissimi F, Perri P, Iaria M, Dominioni T, Zanello M, Conci S, Molfino S, LaBarba G, Ferrari C, Germani P, Patauner S, Pinotti E, Lodo E, Garatti M, Sciannamea I, Troci A, Conticchio M, Floridi A, Chiarelli M, Fumagalli L, Memeo R, Crespi M, Antonucci A, Zimmitti G, Zanus G, Zago M, Frena A, Tarchi P, Griseri G, Ercolani G, Baiocchi GL, Ruzzenente A, Jovine E, Maestri M, DallaValle R, Grazi GL, Giuliante F, Aldrighetti L, Torzilli G, Romano F;  HE. RC.O.LE.S. Group. Hepatocellular carcinoma surgical and oncological trends in a national multicentric population: the HERCOLES experience. Updates Surg. 2020;72:399-411. [PMID: 32170630 DOI: 10.1007/s13304-020-00733-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
108 Chen SL, Xiao H, Xie ZL, Shen JX, Chen ZB, Wang YQ, Li B, Peng ZW, Kuang M, Lai JM, Peng S. The presence of microvascular invasion guides treatment strategy in recurrent HBV-related HCC. Eur Radiol 2020;30:3473-85. [PMID: 32048035 DOI: 10.1007/s00330-019-06640-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
109 Kokudo N, Kokudo T, Hasegawa K. Role of Liver Resection for Hepatocellular Carcinoma with Vascular Invasion: Emerging Evidence from Western Countries. Liver Cancer 2021;10:404-6. [PMID: 34721503 DOI: 10.1159/000517418] [Reference Citation Analysis]
110 Brunner TB, Croner RS. [Neoadjuvant radiotherapy improves overall survival and disease-free interval in resectable hepatocellular carcinoma with portal vein tumor thrombosis]. Strahlenther Onkol 2020;196:194-6. [PMID: 31873778 DOI: 10.1007/s00066-019-01570-2] [Reference Citation Analysis]
111 Ban D, Ogura T, Akahoshi K, Tanabe M. Current topics in the surgical treatments for hepatocellular carcinoma. Ann Gastroenterol Surg 2018;2:137-46. [PMID: 29863117 DOI: 10.1002/ags3.12065] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
112 Kudo M, Kawamura Y, Hasegawa K, Tateishi R, Kariyama K, Shiina S, Toyoda H, Imai Y, Hiraoka A, Ikeda M, Izumi N, Moriguchi M, Ogasawara S, Minami Y, Ueshima K, Murakami T, Miyayama S, Nakashima O, Yano H, Sakamoto M, Hatano E, Shimada M, Kokudo N, Mochida S, Takehara T. Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update. Liver Cancer 2021;10:181-223. [PMID: 34239808 DOI: 10.1159/000514174] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
113 Zhang XP, Gao YZ, Chen ZH, Wang K, Cheng YQ, Guo WX, Shi J, Zhong CQ, Zhang F, Cheng SQ. In-hospital Mortality after Surgical Resection in Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus. J Cancer 2019;10:72-80. [PMID: 30662527 DOI: 10.7150/jca.27102] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
114 Kokudo N, Takemura N, Hasegawa K, Takayama T, Kubo S, Shimada M, Nagano H, Hatano E, Izumi N, Kaneko S, Kudo M, Iijima H, Genda T, Tateishi R, Torimura T, Igaki H, Kobayashi S, Sakurai H, Murakami T, Watadani T, Matsuyama Y. Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update. Hepatol Res. 2019;49:1109-1113. [PMID: 31336394 DOI: 10.1111/hepr.13411] [Cited by in Crossref: 111] [Cited by in F6Publishing: 102] [Article Influence: 37.0] [Reference Citation Analysis]
115 Nevarez NM, Yopp AC. Challenging the Treatment Paradigm: Selecting Patients for Surgical Management of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. J Hepatocell Carcinoma 2021;8:851-60. [PMID: 34350140 DOI: 10.2147/JHC.S291530] [Reference Citation Analysis]
116 Nakamura M, Ito K, Takemura N, Mihara F, Kokudo N. Hepatectomy for liver metastases from cervical cancer with portal vein tumor thrombosis: a case report. Clin J Gastroenterol 2022. [PMID: 35192190 DOI: 10.1007/s12328-022-01603-x] [Reference Citation Analysis]
117 Luo J, Xu L, Li L, Zhang J, Zhang M, Xu M. Comparison of treatments for hepatocellular carcinoma patients with portal vein thrombosis: a systematic review and network meta-analysis. Ann Transl Med 2021;9:1450. [PMID: 34734002 DOI: 10.21037/atm-21-3937] [Reference Citation Analysis]
118 Berardi G, Guglielmo N, Colasanti M, Meniconi RL, Ferretti S, Mariano G, Usai S, Angrisani M, Pecoraro A, Lucarini A, Gasparoli C, Ettorre GM. Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) for advanced hepatocellular carcinoma with macrovascular invasion. Updates Surg 2022. [PMID: 35305261 DOI: 10.1007/s13304-022-01277-7] [Reference Citation Analysis]
119 Vitale A, Trevisani F, Farinati F, Cillo U. Treatment of Hepatocellular Carcinoma in the Precision Medicine Era: From Treatment Stage Migration to Therapeutic Hierarchy. Hepatology 2020;72:2206-18. [PMID: 32064645 DOI: 10.1002/hep.31187] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 23.0] [Reference Citation Analysis]
120 Liu F, Guo X, Dong W, Zhang W, Wei S, Zhang S, Zhu X, Zhou W, Zhang J, Liu H. Postoperative adjuvant TACE-associated nomogram for predicting the prognosis of resectable Hepatocellular Carcinoma with portal vein Tumor Thrombus after Liver Resection. Int J Biol Sci 2020;16:3210-20. [PMID: 33162826 DOI: 10.7150/ijbs.46896] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
121 Wei X, Jiang Y, Zhang X, Feng S, Zhou B, Ye X, Xing H, Xu Y, Shi J, Guo W, Zhou D, Zhang H, Sun H, Huang C, Lu C, Zheng Y, Meng Y, Huang B, Cong W, Lau WY, Cheng S. Neoadjuvant Three-Dimensional Conformal Radiotherapy for Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Randomized, Open-Label, Multicenter Controlled Study. J Clin Oncol 2019;37:2141-51. [PMID: 31283409 DOI: 10.1200/JCO.18.02184] [Cited by in Crossref: 39] [Cited by in F6Publishing: 28] [Article Influence: 13.0] [Reference Citation Analysis]
122 Yang JD, Heimbach JK. New advances in the diagnosis and management of hepatocellular carcinoma. BMJ. [DOI: 10.1136/bmj.m3544] [Cited by in Crossref: 13] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
123 Levi Sandri GB, Vennarecci G, Lepiane P, Ettorre GM. Associating liver partition and portal vein ligation for bleeding hepatocellular carcinoma in HBV cirrhosis: a safety strategy. Transl Gastroenterol Hepatol 2017;2:20. [PMID: 28447055 DOI: 10.21037/tgh.2017.03.08] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
124 Wang YC, Lee JC, Wu TH, Cheng CH, Lee CF, Wu TJ, Chou HS, Chan KM, Lee WC. Improving outcomes of liver resection for hepatocellular carcinoma associated with portal vein tumor thrombosis over the evolving eras of treatment. World J Surg Oncol 2021;19:313. [PMID: 34702312 DOI: 10.1186/s12957-021-02425-w] [Reference Citation Analysis]
125 Kokudo T, Hasegawa K, Shirata C, Tanimoto M, Ishizawa T, Kaneko J, Akamatsu N, Arita J, Demartines N, Uldry E, Kokudo N, Halkic N. Assessment of Preoperative Liver Function for Surgical Decision Making in Patients with Hepatocellular Carcinoma. Liver Cancer 2019;8:447-56. [PMID: 31799202 DOI: 10.1159/000501368] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
126 Cao B, Hao P, Guo W, Ye X, Li Q, Su X, Li L, Zeng J. A predictive model for blood transfusion during liver resection. European Journal of Surgical Oncology 2022. [DOI: 10.1016/j.ejso.2022.01.013] [Reference Citation Analysis]
127 Giovanardi F, Lai Q, Bertacco A, Vitale A. Resection for hepatocellular cancer: overpassing old barriers. Transl Gastroenterol Hepatol 2018;3:64. [PMID: 30363682 DOI: 10.21037/tgh.2018.09.13] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
128 Ogasawara S, Koroki K, Makishima H, Wakatsuki M, Takahashi A, Yumita S, Nakagawa M, Ishino T, Ogawa K, Fujiwara K, Iwanaga T, Sakuma T, Fujita N, Kojima R, Kanzaki H, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Nakagawa R, Nakamoto S, Muroyama R, Chiba T, Ozawa Y, Kawasaki Y, Kurokawa T, Hanaoka H, Tsuji H, Kato N. Durvalumab with or without tremelimumab combined with particle therapy for advanced hepatocellular carcinoma with macrovascular invasion: protocol for the DEPARTURE phase Ib trial. BMJ Open 2022;12:e059779. [PMID: 35396315 DOI: 10.1136/bmjopen-2021-059779] [Reference Citation Analysis]
129 Giannini EG, Bucci L, Garuti F, Brunacci M, Lenzi B, Valente M, Caturelli E, Cabibbo G, Piscaglia F, Virdone R, Felder M, Ciccarese F, Foschi FG, Sacco R, Svegliati Baroni G, Farinati F, Rapaccini GL, Olivani A, Gasbarrini A, Di Marco M, Morisco F, Zoli M, Masotto A, Borzio F, Benvegnù L, Marra F, Colecchia A, Nardone G, Bernardi M, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group. Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice. Hepatology 2018;67:1784-96. [PMID: 29159910 DOI: 10.1002/hep.29668] [Cited by in Crossref: 63] [Cited by in F6Publishing: 63] [Article Influence: 15.8] [Reference Citation Analysis]
130 Chen H, Tao M, Li D, Han J, Cheng C, Ma Y, Wu Y, Shelat VG, Tustumi F, Satapathy SK, Kang KJ, Wang Q. An evaluation of the reporting quality in clinical practice guidelines for hepatocellular carcinoma using the RIGHT checklist. Ann Transl Med 2021;9:1004. [PMID: 34277804 DOI: 10.21037/atm-21-2611] [Reference Citation Analysis]
131 Bertacco A, Vitale A, Mescoli C, Cillo U. Sorafenib treatment has the potential to downstage advanced hepatocellular carcinoma before liver resection. Per Med 2020;17:83-7. [PMID: 32157952 DOI: 10.2217/pme-2018-0114] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
132 Kokudo T, Hasegawa K, Matsuyama Y, Takayama T, Izumi N, Kadoya M, Kudo M, Kubo S, Sakamoto M, Nakashima O, Kumada T, Kokudo N; Liver Cancer Study Group of Japan. Liver resection for hepatocellular carcinoma associated with hepatic vein invasion: A Japanese nationwide survey. Hepatology 2017;66:510-7. [PMID: 28437844 DOI: 10.1002/hep.29225] [Cited by in Crossref: 82] [Cited by in F6Publishing: 76] [Article Influence: 16.4] [Reference Citation Analysis]
133 Chen J, Huang J, Chen M, Yang K, Chen J, Wang J, Xu L, Zhou Z, Zhang Y. Transcatheter arterial chemoembolization (TACE) versus hepatectomy in hepatocellular carcinoma with macrovascular invasion: a meta-analysis of 1683 patients. J Cancer 2017;8:2984-91. [PMID: 28928890 DOI: 10.7150/jca.20978] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
134 Sposito C, Mazzaferro V. The SIRveNIB and SARAH trials, radioembolization vs. sorafenib in advanced HCC patients: reasons for a failure, and perspectives for the future. Hepatobiliary Surg Nutr 2018;7:487-9. [PMID: 30652096 DOI: 10.21037/hbsn.2018.10.06] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 5.8] [Reference Citation Analysis]
135 Zhang XP, Chen ZH, Zhou TF, Li LQ, Chen MS, Wen TF, Shi J, Guo WX, Wu MC, Lau WY, Cheng SQ; Chinese National Research Cooperative Group for Diagnosis and Treatment of Hepatocellular Carcinoma with Tumour Thrombus. A nomogram to predict early postoperative recurrence of hepatocellular carcinoma with portal vein tumour thrombus after R0 liver resection: A large-scale, multicenter study. Eur J Surg Oncol 2019;45:1644-51. [PMID: 30982657 DOI: 10.1016/j.ejso.2019.03.043] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 4.7] [Reference Citation Analysis]
136 Agrawal S. Looking Beyond Sorafenib to Treat Advanced Hepatocellular Carcinoma. J Clin Exp Hepatol 2016;6:339-42. [PMID: 28003728 DOI: 10.1016/j.jceh.2016.11.001] [Reference Citation Analysis]
137 Hatano E, Uemoto S, Yamaue H, Yamamoto M; the Japanese Society of Hepato-Biliary-Pancreatic Surgery. Significance of hepatic resection and adjuvant hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombus in the first branch of portal vein and the main portal trunk: a project study for hepatic surgery of the Jap. J Hepatobiliary Pancreat Sci 2018;25:395-402. [DOI: 10.1002/jhbp.574] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
138 Fu S, Pan M, Zhang J, Zhang H, Tang Z, Li Y, Mu W, Huang J, Dong D, Duan C, Li X, Wang S, Chen X, He X, Yan J, Lu L, Tian J. Deep Learning-Based Prediction of Future Extrahepatic Metastasis and Macrovascular Invasion in Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:1065-76. [PMID: 34513748 DOI: 10.2147/JHC.S319639] [Reference Citation Analysis]
139 Zhang XP, Wang K, Guo WX, Chen ZH, Cheng SQ. Is Sorafenib an Optimal Treatment for Hepatocellular Carcinoma With Macrovascular Invasion or Metastatic Disease? Hepatology 2018;68:786. [PMID: 29500904 DOI: 10.1002/hep.29862] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
140 Zhong JH, Torzilli G, Xing H, Li C, Han J, Liang L, Zhang H, Dai SY, Li LQ, Shen F, Yang T. Controversies and evidence of hepatic resection for hepatocellular carcinoma. BBA Clin. 2016;6:125-130. [PMID: 27761414 DOI: 10.1016/j.bbacli.2016.10.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
141 Zhang F, Lu C, Zhang X, Chen Z, Zhong C, Hu Y, Wei X, Zhou B, Wang K, Chai Z, Wu M, Lau WY, Cheng S. The impact of portal vein tumor thrombus on long-term survival after liver resection for primary hepatic malignancy. HPB 2020;22:1025-33. [DOI: 10.1016/j.hpb.2019.10.2439] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
142 Xiao H, Li JL, Chen SL, Tang MM, Zhou Q, Wu TF, Li X, Peng ZW, Feng ST, Peng S, Kuang M. A Pre-Operative Prognostic Score for Patients With Advanced Hepatocellular Carcinoma Who Underwent Resection. Front Oncol 2021;11:569515. [PMID: 33718130 DOI: 10.3389/fonc.2021.569515] [Reference Citation Analysis]
143 Yu JI, Yoo GS, Cho S, Jung SH, Han Y, Park S, Lee B, Kang W, Sinn DH, Paik YH, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Park HC. Initial clinical outcomes of proton beam radiotherapy for hepatocellular carcinoma. Radiat Oncol J. 2018;36:25-34. [PMID: 29580046 DOI: 10.3857/roj.2017.00409] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
144 Lee BH, Lee DS, Cho CW, Yun SS. Role and limitation of neoadjuvant hepatic arterial infusion chemotherapy in advanced hepatocelluar carcinoma patients with Child-Pugh class A. World J Surg Oncol 2019;17:143. [PMID: 31416447 DOI: 10.1186/s12957-019-1685-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
145 Orimo T, Kamiyama T, Wakayama K, Shimada S, Nagatsu A, Asahi Y, Sakamoto Y, Kamachi H, Taketomi A. Hepatectomy Combined with Diaphragmatic Resection for Hepatocellular Carcinoma with Diaphragmatic Involvement: A Propensity Score-Matched Analysis. Ann Surg Oncol 2020;27:4153-63. [PMID: 32588266 DOI: 10.1245/s10434-020-08754-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
146 Wang HL, Cucchetti A, Zhong JH, Ye XP, Gu JH, Ma L, Peng NF, Li LQ. Should hepatic resection be recommended to patients with hepatocellular carcinoma and portal vein invasion? J Hepatol. 2016;65:1057-1058. [PMID: 27475616 DOI: 10.1016/j.jhep.2016.07.022] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
147 Yi NJ. Inspiration of liver resection for hepatocellular carcinoma associated with hepatic vein invasion, not inferior vena cava invasion. Hepatobiliary Surg Nutr 2018;7:392-4. [PMID: 30498716 DOI: 10.21037/hbsn.2018.07.02] [Reference Citation Analysis]
148 Vennarecci G, Ferraro D, Tudisco A, Levi Sandri GB, Guglielmo N, Berardi G, Sperduti I, Ettorre GM. The ALPPS procedure: hepatocellular carcinoma as a main indication. An Italian single-center experience. Updates Surg 2019;71:67-75. [DOI: 10.1007/s13304-018-0596-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
149 Khan AR, Wei X, Xu X. Portal Vein Tumor Thrombosis and Hepatocellular Carcinoma - The Changing Tides. J Hepatocell Carcinoma 2021;8:1089-115. [PMID: 34522691 DOI: 10.2147/JHC.S318070] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
150 Li WF, Yen YH, Liu YW, Wang CC, Yong CC, Lin CC, Cheng YF, Wang JH, Lu SN. Preoperative predictors of early recurrence after resection for hepatocellular carcinoma. Am J Surg 2021:S0002-9610(21)00471-2. [PMID: 34399978 DOI: 10.1016/j.amjsurg.2021.08.012] [Reference Citation Analysis]
151 Jia J, Sun J, Duan X, Li W. Clinical Values and Markers of Radiation-Induced Liver Disease for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus Treated With Stereotactic Body Radiotherapy. Front Oncol 2021;11:760090. [PMID: 34970485 DOI: 10.3389/fonc.2021.760090] [Reference Citation Analysis]
152 Kokudo T, Kokudo N, Hasegawa K. Negative phase 3 study of 90 Y microspheres versus sorafenib in HCC. The Lancet Oncology 2018;19:e68. [DOI: 10.1016/s1470-2045(18)30026-3] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
153 Cerrito L, Annicchiarico BE, Iezzi R, Gasbarrini A, Pompili M, Ponziani FR. Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers. World J Gastroenterol 2019; 25(31): 4360-4382 [PMID: 31496618 DOI: 10.3748/wjg.v25.i31.4360] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 20] [Article Influence: 9.7] [Reference Citation Analysis]
154 Su K, Gu T, Xu K, Wang J, Liao H, Li X, Wen L, Song Y, Zhong J, He B, Liu X, He J, Liu Y, Li Q, Feng X, Chen S, Yang B, Huang W, Jin H, Luo X, Hu T, Chen J, Wu Z, Lu S, Zhang J, Rao M, Xie Y, Wang J, Zhu X, Chen L, Li B, Su S, Yang X, Wang J, Zeng H, Wang P, Yan M, Chen X, He K, Han Y. Gamma knife radiosurgery versus transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a propensity score matching study. Hepatol Int 2022. [PMID: 35729469 DOI: 10.1007/s12072-022-10339-2] [Reference Citation Analysis]
155 Li S, Guo JH, Lu J, Wang C, Wu H, Wang H, Zha J, Fan R. I125 irradiation stent for treatment of hepatocellular carcinoma with portal vein thrombosis: A meta-analysis. Cancer Radiother 2021;25:340-9. [PMID: 33455874 DOI: 10.1016/j.canrad.2020.12.003] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
156 Chen ZH, Zhang XP, Lu YG, Li LQ, Chen MS, Wen TF, Jia WD, Zhou D, Li J, Yang DH, Zhen ZJ, Xia YJ, Fan RF, Huang YQ, Zhang Y, Wu XJ, Hu YR, Tang YF, Lin JH, Zhang F, Zhong CQ, Guo WX, Shi J, Lau J, Cheng SQ. Actual long-term survival in HCC patients with portal vein tumor thrombus after liver resection: a nationwide study. Hepatol Int 2020;14:754-64. [PMID: 32253678 DOI: 10.1007/s12072-020-10032-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
157 Ye JZ, Wang YY, Bai T, Chen J, Xiang BD, Wu FX, Li LQ. Surgical resection for hepatocellular carcinoma with portal vein tumor thrombus in the Asia-Pacific region beyond the Barcelona Clinic Liver Cancer treatment algorithms: a review and update. Oncotarget. 2017;8:93258-93278. [PMID: 29190996 DOI: 10.18632/oncotarget.18735] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
158 Gan W, Huang JL, Zhang MX, Fu YP, Yi Y, Jing CY, Fan J, Zhou J, Qiu SJ. New nomogram predicts the recurrence of hepatocellular carcinoma in patients with negative preoperative serum AFP subjected to curative resection. J Surg Oncol 2018;117:1540-7. [PMID: 29572833 DOI: 10.1002/jso.25046] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 5.5] [Reference Citation Analysis]
159 Peng SY, Wang XA, Huang CY, Li JT, Hong DF, Wang YF, Xu B. Better surgical treatment method for hepatocellular carcinoma with portal vein tumor thrombus. World J Gastroenterol 2018; 24(40): 4527-4535 [PMID: 30386102 DOI: 10.3748/wjg.v24.i40.4527] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
160 Martins-filho SN, Alves VAF. The strengths and weaknesses of gross and histopathological evaluation in hepatocellular carcinoma: a brief review. Surg Exp Pathol 2019;2. [DOI: 10.1186/s42047-019-0047-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
161 Feng JK, Wu YX, Chen ZH, Sun JX, Wang K, Chai ZT, Shi J, Guo WX, Cheng SQ. The effect of bile duct tumor thrombus on the long-term prognosis of hepatocellular carcinoma patients after liver resection: a systematic review and meta-analysis. Ann Transl Med 2020;8:1683. [PMID: 33490195 DOI: 10.21037/atm-20-4698] [Reference Citation Analysis]
162 Kokudo T, Hasegawa K. Evaluating the liver function of patients with hepatocellular carcinoma. Hepatol Res 2021;51:1095-6. [PMID: 34724293 DOI: 10.1111/hepr.13705] [Reference Citation Analysis]
163 Lee D, Lee HC, An J, Shim JH, Kim KM, Lim YS, Chung YH, Lee YS. Comparison of surgical resection versus transarterial chemoembolization with additional radiation therapy in patients with hepatocellular carcinoma with portal vein invasion. Clin Mol Hepatol 2018;24:144-50. [PMID: 29665630 DOI: 10.3350/cmh.2017.0041] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
164 Huang Z, Zhou JK, Peng Y, He W, Huang C. The role of long noncoding RNAs in hepatocellular carcinoma. Mol Cancer 2020;19:77. [PMID: 32295598 DOI: 10.1186/s12943-020-01188-4] [Cited by in Crossref: 62] [Cited by in F6Publishing: 73] [Article Influence: 31.0] [Reference Citation Analysis]
165 Zhang ZY, Zhang EL, Zhang BX, Zhang W. Surgery for hepatocellular carcinoma with tumor thrombosis in inferior vena cava: A case report. World J Clin Cases 2021; 9(36): 11495-11503 [DOI: 10.12998/wjcc.v9.i36.11495] [Reference Citation Analysis]
166 Zhang XP, Gao YZ, Chen ZH, Chen MS, Li LQ, Wen TF, Xu L, Wang K, Chai ZT, Guo WX, Shi J, Xie D, Wu MC, Yee Lau W, Cheng SQ. An Eastern Hepatobiliary Surgery Hospital/Portal Vein Tumor Thrombus Scoring System as an Aid to Decision Making on Hepatectomy for Hepatocellular Carcinoma Patients With Portal Vein Tumor Thrombus: A Multicenter Study. Hepatology 2019;69:2076-90. [PMID: 30586158 DOI: 10.1002/hep.30490] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 16.7] [Reference Citation Analysis]
167 Cao F, Shen L, Qi H, Xie L, Song Z, Chen S, Fan W. Tree-based classification system incorporating the HVTT-PVTT score for personalized management of hepatocellular carcinoma patients with macroscopic vascular invasion. Aging (Albany NY) 2019;11:9544-55. [PMID: 31682230 DOI: 10.18632/aging.102403] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
168 Moriguchi M, Furuta M, Itoh Y. A Review of Non-operative Treatments for Hepatocellular Carcinoma with Advanced Portal Vein Tumor Thrombus. J Clin Transl Hepatol 2017;5:177-83. [PMID: 28660156 DOI: 10.14218/JCTH.2016.00075] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
169 Kaneko S, Tsuchiya K, Yasui Y, Inada K, Kirino S, Yamashita K, Osawa L, Hayakawa Y, Sekiguchi S, Higuchi M, Takaura K, Maeyashiki C, Tamaki N, Takeguchi T, Takeguchi Y, Nagano T, Nakanishi H, Itakura J, Takahashi Y, Himeno Y, Hoshi A, Kurosaki M, Izumi N. Strategy for advanced hepatocellular carcinoma based on liver function and portal vein tumor thrombosis. Hepatol Res 2020;50:1375-85. [DOI: 10.1111/hepr.13567] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
170 Govalan R, Lauzon M, Luu M, Ahn JC, Kosari K, Todo T, Kim IK, Noureddin M, Kuo A, Walid AS, Sundaram V, Lu SC, Roberts LR, Singal AG, Heimbach JK, Agopian VG, Nissen N, Yang JD. Comparison of Surgical Resection and Systemic Treatment for Hepatocellular Carcinoma with Vascular Invasion: National Cancer Database Analysis. Liver Cancer 2021;10:407-18. [PMID: 34721504 DOI: 10.1159/000515554] [Reference Citation Analysis]
171 Li M, Zhao Y, Liu X, Dang Z, Wang X, Jiang Y, Yang Z. Association and interaction between model for end-stage liver disease score and minimally invasive treatment with regard to mortality of patients with hepatitis B virus-associated hepatocellular carcinoma and portal vein tumor thrombi. Oncol Lett 2019;17:119-26. [PMID: 30655746 DOI: 10.3892/ol.2018.9590] [Reference Citation Analysis]
172 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236. [PMID: 29628281 DOI: 10.1016/j.jhep.2018.03.019] [Cited by in Crossref: 2122] [Cited by in F6Publishing: 1974] [Article Influence: 530.5] [Reference Citation Analysis]
173 Tao ZW, Cheng BQ, Zhou T, Gao YJ. Management of hepatocellular carcinoma patients with portal vein tumor thrombosis: A narrative review. Hepatobiliary Pancreat Dis Int 2021:S1499-3872(21)00229-0. [PMID: 34955380 DOI: 10.1016/j.hbpd.2021.12.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
174 Sakamoto K, Nagano H. Surgical treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus. Hepatol Res. 2017;47:957-962. [PMID: 28618075 DOI: 10.1111/hepr.12923] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
175 Gon H, Kido M, Tanaka M, Kinoshita H, Komatsu S, Tsugawa D, Awazu M, Toyama H, Matsumoto I, Itoh T, Fukumoto T. Growth velocity of the portal vein tumor thrombus accelerated by its progression, alpha-fetoprotein level, and liver fibrosis stage in patients with hepatocellular carcinoma. Surgery 2018;164:1014-22. [DOI: 10.1016/j.surg.2018.06.025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
176 Koga Y, Beppu T, Imai K, Kuramoto K, Miyata T, Kitano Y, Nakagawa S, Okabe H, Okabe K, Yamashita YI, Chikamoto A, Baba H. Complete remission of advanced hepatocellular carcinoma following transient chemoembolization and portal vein ligation. Surg Case Rep 2018;4:102. [PMID: 30159613 DOI: 10.1186/s40792-018-0510-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
177 Serenari M, Cappelli A, Cucchetti A, Mosconi C, Strigari L, Monari F, Ravaioli M, Rizzini EL, Fanti S, Golfieri R, Cescon M. Deceased Donor Liver Transplantation After Radioembolization for Hepatocellular Carcinoma and Portal Vein Tumoral Thrombosis: A Pilot Study. Liver Transpl 2021. [PMID: 34355489 DOI: 10.1002/lt.26257] [Reference Citation Analysis]
178 He C, Ge N, Wang X, Li H, Chen S, Yang Y. Conversion Therapy of Large Unresectable Hepatocellular Carcinoma With Ipsilateral Portal Vein Tumor Thrombus Using Portal Vein Embolization Plus Transcatheter Arterial Chemoembolization. Front Oncol 2022;12:923566. [DOI: 10.3389/fonc.2022.923566] [Reference Citation Analysis]
179 Mei J, Li SH, Wang QX, Lu LH, Ling YH, Zou JW, Lin WP, Wen YH, Wei W, Guo RP. Resection vs. Sorafenib for Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Real World, Propensity Score Matched Analytic Study. Front Oncol 2020;10:573. [PMID: 32432036 DOI: 10.3389/fonc.2020.00573] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
180 Yokota T, Nojima H, Kuboki S, Yoshitomi H, Furukawa K, Takayashiki T, Takano S, Ohtsuka M. Sphingosine-1-phosphate Receptor-1 Promotes Vascular Invasion and EMT in Hepatocellular Carcinoma. J Surg Res 2021;259:200-10. [PMID: 33307511 DOI: 10.1016/j.jss.2020.11.044] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
181 Luo F, Li M, Ding J, Zheng S. The Progress in the Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus. Front Oncol 2021;11:635731. [PMID: 34631513 DOI: 10.3389/fonc.2021.635731] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
182 Zhang XP, Wang K, Gao YZ, Wei XB, Lu CD, Chai ZT, Zhen ZJ, Li J, Yang DH, Zhou D, Fan RF, Yan ML, Xia YJ, Liu B, Huang YQ, Zhang F, Hu YR, Zhong CQ, Lin JH, Fang KP, Cheng ZH, Wu MC, Lau WY, Cheng SQ; Chinese National Research Cooperative Group for Diagnosis and Treatment of Hepatocellular Carcinoma with Tumour Thrombus. Prognostic model for identifying candidates for hepatectomy among patients with hepatocellular carcinoma and hepatic vein invasion. Br J Surg 2020;107:865-77. [PMID: 32246475 DOI: 10.1002/bjs.11524] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
183 Lin Q, Huang X, Zhong C, Luo T, Zeng X, Chen S. Improved survival with radiotherapy in hepatocellular carcinoma with major vascular invasion: A propensity-matched analysis of Surveillance, Epidemiology, and End Results database. Cancer Med 2019;8:515-26. [PMID: 30656831 DOI: 10.1002/cam4.1937] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
184 Yang T, Melloul E, Tabrizian P, Schwartz M. Expanded Criteria for Resection: Are Current Guidelines Too Conservative? Curr Hepatology Rep 2016;15:323-6. [DOI: 10.1007/s11901-016-0322-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
185 Shirata C, Hasegawa K, Kokudo T, Yamashita S, Yamamoto S, Arita J, Akamatsu N, Kaneko J, Sakamoto Y, Kokudo N. Liver Resection for Hepatocellular Carcinoma in Patients with Renal Dysfunction. World J Surg. 2018;42:4054-4062. [PMID: 29947980 DOI: 10.1007/s00268-018-4698-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
186 Zhang L, Hu B, Li W, Huang P, Zhang S, Zhong BY, Ni CF. 125I Irradiation Stent for Hepatocellular Carcinoma with Main Portal Vein Tumor Thrombosis: A Systematic Review. Cardiovasc Intervent Radiol 2020;43:196-203. [PMID: 31602496 DOI: 10.1007/s00270-019-02346-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
187 Li C, Shen JY, Zhang XY, Peng W, Wen TF, Yang JY, Yan LN. Predictors of Futile Liver Resection for Patients with Barcelona Clinic Liver Cancer Stage B/C Hepatocellular Carcinoma. J Gastrointest Surg. 2018;22:496-502. [PMID: 29119530 DOI: 10.1007/s11605-017-3632-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
188 Liang L, Quan B, Wu H, Diao YK, Li J, Chen TH, Zhang YM, Zhou YH, Zhang WG, Wang H, Serenari M, Cescon M, Schwartz M, Zeng YY, Liang YJ, Jia HD, Xing H, Li C, Wang MD, Yan WT, Chen WY, Lau WY, Zhang CW, Pawlik TM, Huang DS, Shen F, Yang T. Development and validation of an individualized prediction calculator of postoperative mortality within 6 months after surgical resection for hepatocellular carcinoma: an international multicenter study. Hepatol Int 2021;15:459-71. [PMID: 33534082 DOI: 10.1007/s12072-021-10140-7] [Reference Citation Analysis]
189 Cheng S, Chen M, Cai J, Sun J, Guo R, Bi X, Lau WY, Wu M. Chinese Expert Consensus on Multidisciplinary Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus (2018 Edition). Liver Cancer 2020;9:28-40. [PMID: 32071907 DOI: 10.1159/000503685] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 6.7] [Reference Citation Analysis]
190 Zu Q, Schenning RC, Jahangiri Y, Tomozawa Y, Kolbeck KJ, Kaufman JA, Al-Hakim R, Naugler WE, Nabavizadeh N, Kardosh A, Billingsley KG, Mayo SC, Orloff SL, Enestvedt KK, Maynard E, Ahn J, Lhewa D, Farsad K. Yttrium-90 Radioembolization for BCLC Stage C Hepatocellular Carcinoma Comparing Child-Pugh A Versus B7 Patients: Are the Outcomes Equivalent? Cardiovasc Intervent Radiol 2020;43:721-31. [PMID: 32140840 DOI: 10.1007/s00270-020-02434-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
191 Wei Q, Zhao L, Jiang L, Bi J, Yu Z, Zhao L, Song X, Sun M, Chen Y, Wei M. Prognostic relevance of miR-137 and its liver microenvironment regulatory target gene AFM in hepatocellular carcinoma. J Cell Physiol 2019;234:11888-99. [PMID: 30523640 DOI: 10.1002/jcp.27855] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
192 Shinkawa H, Tanaka S, Takemura S, Ishihara T, Yamamoto K, Kubo S. Tumor Size Drives the Prognosis After Hepatic Resection of Solitary Hepatocellular Carcinoma Without Vascular Invasion. J Gastrointest Surg 2020;24:1040-8. [PMID: 31197685 DOI: 10.1007/s11605-019-04273-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
193 Galun D, Mijac D, Filipovic A, Bogdanovic A, Zivanovic M, Masulovic D. Precision Medicine for Hepatocellular Carcinoma: Clinical Perspective. JPM 2022;12:149. [DOI: 10.3390/jpm12020149] [Reference Citation Analysis]
194 Zane KE, Makary MS. Locoregional Therapies for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. Cancers (Basel) 2021;13:5430. [PMID: 34771593 DOI: 10.3390/cancers13215430] [Reference Citation Analysis]
195 Costentin CE, Decaens T, Laurent A, Nault J, Paule B, Letoublon C, Luciani A, Calderaro J, Adam R, Bricault I, Amaddeo G, Cherqui D, Mallat A, Samuel D, Duvoux C, Ganne-carrié N, Roudot-thoraval F, Vibert E. Sorafenib vs surgical resection for hepatocellular carcinoma with macrovascular invasion: A propensity score analysis. Liver Int 2017;37:1869-76. [DOI: 10.1111/liv.13491] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
196 Xu J, Hong J, Wang Y, Zhou L, Xu B, Si Y, He Y, Chen Y. Prognostic Influence of Spontaneous Tumor Rupture in Patients With Hepatocellular Carcinoma After Hepatectomy: A Meta-Analysis of Observational Studies. Front Surg 2021;8:769233. [PMID: 34869566 DOI: 10.3389/fsurg.2021.769233] [Reference Citation Analysis]
197 Xu W, Guo R, Xu G, Sun L, Hu D, Xu H, Yang H, Sang X, Lu X, Mao Y. Management of intrahepatic recurrence after resection for hepatocellular carcinoma exceeding the barcelona clinic liver cancer criteria. Oncotarget 2017;8:110406-14. [PMID: 29299157 DOI: 10.18632/oncotarget.22779] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
198 Tsilimigras DI, Sahara K, Moris D, Mehta R, Paredes AZ, Ratti F, Marques HP, Soubrane O, Lam V, Poultsides GA, Popescu I, Alexandrescu S, Martel G, Workneh A, Guglielmi A, Hugh T, Aldrighetti L, Weiss M, Bauer TW, Maithel SK, Pulitano C, Shen F, Koerkamp BG, Endo I, Pawlik TM. Assessing Textbook Outcomes Following Liver Surgery for Primary Liver Cancer Over a 12-Year Time Period at Major Hepatobiliary Centers. Ann Surg Oncol 2020;27:3318-27. [DOI: 10.1245/s10434-020-08548-w] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]